Medical device company focused on developing restoration treatments for patients with spinal cord-injuries

 

 

Dr. Richard Toselli, CEO of the InVivo Therapeutics Corporation a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries joins eHealth Radio and the Health News & Spinal Health Channels.

 

Listen to interview with host Eric Michaels and guest Dr. Richard Toselli discuss the following:

1. Can you tell our audience about InVivo Therapeutics and what your company does?
2. You have an interesting background for a CEO, not a typical one. You’re a former neuro surgeon. Can you tell our audience which has an interest in healthcare and business a bit about your background and how it translates to your current role as CEO of InVivo Therapeutics?
3. What’s more difficult and challenging being a neuro-surgeon or the ceo of a publicly traded company haha?
4. You became CEO earlier this year, and reading some news on you and the company it was reported that you have made some major changes with the company under your leadership such as decreasing the cash burn rate, launching a second spinal trial. Can you discuss that and also discuss the second trial as well.
5. Can you talk a bit about product development with your company and how the process works so our listeners can understand.
6. The spinal chord industry is constantly evolving and changing. Can you chat a bit about the industry and where it’s going and where your company fits within this industry.
7. We know wall street is not always patient. How do companies like yours juggle the interests of investors with what you do with research and development and clinical trials etc.
8. Where do you see this company going in the next 3 to 5 years, what do you hope to accomplish.

 

Prior to joining InVivo, Dr. Toselli served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory, and medical affairs teams reporting to the CEO. Prior to that, Dr. Toselli served five years at Sanofi in various levels of increasing responsibility, including Vice President of Global Medical Affairs – Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery.

Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Surgical, and earlier held various roles at DePuy Spine including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. He subsequently held the position of Vice President of Evidence-Based Medicine at Johnson & Johnson for the device sector.

Dr. Toselli’s previous academic positions include Assistant Professor at Brown University, Associate Professor, Director of Spine Center, and Associate Chief of Staff at the University of North Carolina (UNC), and Associate Professor at the University of Vermont. He holds a bachelor of arts from Providence College, his medical degree from Brown University, and a masters of business administration from the UNC’s Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.

InVivo Therapeutics Holdings Corporation is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In January 2018, the company announced updated clinical evidence, including improvements in patients with acute spinal cord injury (SCI), from its INSPIRE study of the Neuro-Spinal Scaffold™. The publicly traded company is headquartered in Cambridge, MA.

 

 

Website: www.invivotherapeutics.com

• Likes
• Download
• Share